CERE MERGER ANNOUNCEMENT: Julie & Holleman LLP Announces Investigation Into Potential Claims Regarding AbbVie's Proposed Acquisition of Cerevel Therapeutics
NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Julie & Holleman LLP, a nationally recognized shareholder rights law firm, is investigating the proposed $45 per share sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. The firm has already identified potential conflicts of interest related to the merger.
For a free consultation and to learn about our investigation, click here or visit: https://julieholleman.com/?p=3218
On December 6, 2023, Cerevel announced that it had entered into an agreement for the company to be acquired by AbbVie for $45 per share, or a total of $8.7 billion. The transaction, which is subject to shareholder approval, is expected to close in mid-2024.
Julie & Holleman, whose attorneys have helped secure hundreds of millions of dollars for shareholders, is concerned about potential conflicts, including related to Cerevel's largest shareholder, Bain Capital.
If you would like more information about our investigation, please contact W. Scott Holleman at scott@julieholleman.com or (917) 325-3798, or submit your information by clicking here.
Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm's attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit https://www.julieholleman.com/. This notice may constitute attorney advertising. Past results do not guarantee future outcomes.
CONTACT INFORMATION
Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cere-merger-announcement-julie--holleman-llp-announces-investigation-into-potential-claims-regarding-abbvies-proposed-acquisition-of-cerevel-therapeutics-302008308.html
SOURCE Julie & Holleman LLP
Ausgewählte Hebelprodukte auf Cerevel Therapeutics
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Cerevel Therapeutics
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Cerevel Therapeutics Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Cerevel Therapeutics Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Cerevel Therapeutics nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.
